468 related articles for article (PubMed ID: 34496363)
1. Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO.
Zaiss M; Uhlig J; Zahn MO; Decker T; Lehmann HC; Harde J; Hogrefe C; Vannier C; Marschner N
Oncol Res Treat; 2021; 44(11):613-621. PubMed ID: 34496363
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
3. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
4. The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP.
Streckmann F; Balke M; Lehmann HC; Rustler V; Koliamitra C; Elter T; Hallek M; Leitzmann M; Steinmetz T; Heinen P; Baumann FT; Bloch W
BMC Cancer; 2018 Jan; 18(1):62. PubMed ID: 29316888
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
[TBL] [Abstract][Full Text] [Related]
6. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
[TBL] [Abstract][Full Text] [Related]
7. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
[TBL] [Abstract][Full Text] [Related]
8. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
9. Electroacupuncture use for treatment of taxane-induced peripheral neuropathy in patients with breast cancer: protocol for a pilot, randomised, blinded, sham-controlled trial (EA for CIPN).
Choi V; Park SB; Lacey J; Kumar S; Heller G; Grimison P
BMJ Open; 2024 Jan; 14(1):e076391. PubMed ID: 38195173
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy-induced pain and neuropathy: a prospective study in patients treated with adjuvant oxaliplatin or docetaxel.
Ventzel L; Jensen AB; Jensen AR; Jensen TS; Finnerup NB
Pain; 2016 Mar; 157(3):560-568. PubMed ID: 26529271
[TBL] [Abstract][Full Text] [Related]
11. Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
Kanai M; Kawaguchi T; Kotaka M; Shinozaki K; Touyama T; Manaka D; Ishigure K; Hasegawa J; Munemoto Y; Matsui T; Takagane A; Ishikawa H; Matsumoto S; Sakamoto J; Saji S; Yoshino T; Ohtsu A; Watanabe T; Matsuda F
Ann Oncol; 2016 Jun; 27(6):1143-1148. PubMed ID: 27069012
[TBL] [Abstract][Full Text] [Related]
12. The relationship between peripheral neuropathy and efficacy in second-line chemotherapy for unresectable advanced gastric cancer: a prospective observational multicenter study protocol (IVY).
Tanioka H; Nagasaka T; Uno F; Inoue M; Okita H; Katata Y; Kanzaki H; Kuramochi H; Satake H; Shindo Y; Doi A; Nasu J; Yamashita H; Yamaguchi Y
BMC Cancer; 2019 Oct; 19(1):941. PubMed ID: 31604467
[TBL] [Abstract][Full Text] [Related]
13. A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients.
Bao T; Seidman AD; Piulson L; Vertosick E; Chen X; Vickers AJ; Blinder VS; Zhi WI; Li Q; Vahdat LT; Dickler MN; Robson ME; Mao JJ
Eur J Cancer; 2018 Sep; 101():12-19. PubMed ID: 30007894
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine Stress Axis-Dependence of Duloxetine Analgesia (Anti-Hyperalgesia) in Chemotherapy-Induced Peripheral Neuropathy.
Staurengo-Ferrari L; Bonet IJM; Araldi D; Green PG; Levine JD
J Neurosci; 2022 Jan; 42(3):405-415. PubMed ID: 34880120
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
Misawa S; Denda T; Kodama S; Suzuki T; Naito Y; Kogawa T; Takada M; Suichi T; Shiosakai K; Kuwabara S;
BMC Cancer; 2023 Nov; 23(1):1098. PubMed ID: 37951905
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer.
Jin L; Zhang Y; Yang W
Int J Gynaecol Obstet; 2020 Jun; 149(3):303-308. PubMed ID: 32133643
[TBL] [Abstract][Full Text] [Related]
17. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer.
Teng C; Cohen J; Egger S; Blinman PL; Vardy JL
Support Care Cancer; 2022 Jan; 30(1):33-47. PubMed ID: 34410459
[TBL] [Abstract][Full Text] [Related]
19. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
20. The updated five-year overall survival and long-term oxaliplatin-related neurotoxicity assessment of the FACOS study.
Takeshita E; Ishibashi K; Koda K; Oda N; Yoshimatsu K; Sato Y; Oya M; Yamaguchi S; Nakajima H; Momma T; Maekawa H; Tsubaki M; Yamada T; Kobayashi M; Tanakaya K; Ishida H
Surg Today; 2021 Aug; 51(8):1309-1319. PubMed ID: 33586034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
